Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)

TipRanks01:30

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive

GlobeNewswireMay 15 19:03

HC Wainwright & Co. : The Unicycive Therapeutics (UNCY.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $4.50.

HC Wainwright & Co. : The Unicycive Therapeutics (UNCY.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $4.50.

Zhitong FinanceMay 15 00:07

Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)

TipRanksMay 14 23:40

Noble Financial Remains a Buy on Unicycive Therapeutics (UNCY)

TipRanksMay 14 20:25

Unicycive Therapeutics Q1 2024 GAAP EPS $(0.61) Misses $(0.15) Estimate

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.15) by 306.67 percent.

BenzingaMay 14 04:38